{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-019381","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-07-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.538035+00:00","generated_at":"2026-06-24T14:39:47.619824+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oncotelic presents Phase 1/2 OT-101 pancreatic cancer data; median OS doubled in patients receiving subsequent chemo","bullets":["55% of OT-101-treated pancreatic cancer patients had long-term disease control (21 of 37 pts).","Median OS doubled to 9.3 vs 2.6 months (p<0.0001) for those who received subsequent chemotherapy.","High AUC associated with improved OS: 9.6 vs 2.4 months (p=0.0006).","OT-101 PK dose proportional (p<0.0001).","Presentation from JCA-AACR conference available on company website and YouTube."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-019381","json":"https://secwatch.observer/filing/0001493152-22-019381.json","markdown":"https://secwatch.observer/filing/0001493152-22-019381.md","text":"https://secwatch.observer/filing/0001493152-22-019381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222019381/0001493152-22-019381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222019381/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T14:39:47.619824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}